The percentage of S100A4‐positive tumors in previous studies in CRC has varied considerably due to different scoring algorithms and cutoffs, patient selection, and technical reasons (e.g., antibodies used and TMAs vs. whole sections). Here, S100A4 is linked to colorectal carcinoma.